Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Published:2015-03 Issue:9973 Volume:385 Page:1075-1086
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lawitz Eric,Gane Edward,Pearlman Brian,Tam Edward,Ghesquiere Wayne,Guyader Dominique,Alric Laurent,Bronowicki Jean-Pierre,Lester Laura,Sievert William,Ghalib Reem,Balart Luis,Sund Fredrik,Lagging Martin,Dutko Frank,Shaughnessy Melissa,Hwang Peggy,Howe Anita Y M,Wahl Janice,Robertson Michael,Barr Eliav,Haber Barbara

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

3. Recommendations for the indentification of chronic hepatitis C virus infection among persons born during 1945–1965;MMWR Morb Mortal Wkly Rep,2012

4. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings;Rein;Ann Intern Med,2012

5. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection;Kim;J Infect Dis,2013

Cited by 261 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

2. Growing Utilization of Radical Chemistry in the Synthesis of Pharmaceuticals;The Chemical Record;2023-08-11

3. Hepatitis C;Encyclopedia of Cell Biology;2023

4. Current Landscape of HCV Therapeutics;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

5. An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study);Health Science Reports;2022-12-05